Efficacy And Safety Of Microwave Therapy For Burning Mouth Syndrome

To explore the efficacy and safety of microwave therapy in treating burning mouth syndrome. The randomized controlled trial was conducted between November 2023 and January 2025, which has received ethical approval from the hospital(KQLW2023007). 61 patients were included in the intention-to-treat analysis, and 53 completed the intervention. The experimental group (n=28) received microwave therapy (2450 MHz, 5-10 W) applied to symptomatic areas, focusing on one site for 5 minutes (up to 25 minutes per session), twice weekly for 4 weeks. The control group (n=25) was administered oral mecobalamin (0.5 mg) three times daily for 4 weeks. Primary outcome was the response rate of pain reduction, as assessed on a visual analogue scale (VAS). Secondary outcomes included changes in oral health quality of life, anxiety, depression, and sleep quality. Data were analyzed using SPSS 28.0, and p < 0.05 was considered statistically significant. The response rate was 89.29% in experimental group and 60% in control group (p < 0.05). Both groups showed reduced VAS scores, and the experimental group had a greater reduction in VAS scores. Microwave therapy also improved oral health quality of life, reduced anxiety and depression (p < 0.05), though sleep quality showed no significant improvement. No severe adverse events were reported. Microwave therapy is an effective and safe option for improving oral mucosal pain symptoms, alleviating anxiety and depression, and enhancing oral health quality of life, which is a promising option for BMS patients.